Current Report Filing (8-k)
February 05 2014 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February
4, 2014
ARIAD
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
0-21696
|
22-3106987
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
26 Landsdowne Street, Cambridge, Massachusetts
|
02139
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant's telephone number, including
area code: (617) 494-0400
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2.
below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 8.01 Other Events.
On January 31, 2014, the Compensation Committee of the Board of
Directors of ARIAD Pharmaceuticals, Inc. (the “Company”) approved equity
awards for officers of the Company, including named executive officers,
based upon the Company’s performance in 2013. Unlike in recent years,
the Compensation Committee did not award any merit salary increases for
2014 or short-term incentive (cash bonus) payments for 2013 performance.
All equity awards were granted under the Company’s 2006 Long-Term
Incentive Plan, as amended. They are intended by the Compensation
Committee to serve the dual purposes of executive retention and
continued alignment of the executives’ incentives with long-term growth
in shareholder value. The awards consist of the following two types of
equity incentives, with the number of shares covered by the awards
determined based on option-equivalent values: 50% issued as time-based
restricted stock units vesting over a three-year period, and 50% issued
as performance shares that will be earned only upon the achievement of
specified commercial and research and development (R&D) milestones. If
earned, the performance share units will vest over a two-year
period. Additional information on these equity awards will be provided
in the Company’s proxy statement for its 2014 annual meeting of
shareholders to be issued this spring.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Edward M. Fitzgerald
|
|
|
|
|
|
Edward M. Fitzgerald
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
|
|
|
|
|
Date:
|
February 4, 2014
|
|
|
|
3
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Jul 2023 to Jul 2024